Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
SSE:600613
Wall Street
Price Targets
Price Targets Summary
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd
Price Targets
Operating Income
Forecast
For the last 13 years the
compound annual growth rate for
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's operating income is
13%.
The projected
CAGR
for the next 10 years is
9%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's stock price target?
Not Available
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd doesn't have any price targets made by Wall Street professionals.
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Revenue forecast?
Projected CAGR
-5%
For the last 13 years the
compound annual growth rate for
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's revenue is
22%.
The projected
CAGR
for the next 10 years is
-5%.
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Operating Income forecast?
Projected CAGR
9%
For the last 13 years the
compound annual growth rate for
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's operating income is
13%.
The projected
CAGR
for the next 10 years is
9%.
What is Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's Net Income forecast?
Projected CAGR
10%
For the last 13 years the
compound annual growth rate for
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's net income is
11%.
The projected
CAGR
for the next 10 years is
10%.
